The treatment of pancreatic stellate cells—the progenitors of CAFs in PDAC—with TGF-β results in the marked upregulation of EGFR and HER2 activation, significantly enhancing the pro-metastatic capacity of myCAFs and promoting cancer cell metastasis in PDAC [50]. The gene discussed is EGFR; the disease is cancer.